Serum Interleukin-5 Changes in Partly Controlled Atopic Asthmatic Children
DOI:
https://doi.org/10.3889/oamjms.2014.037Keywords:
Interleukin-5 (IL-5), Partly controlled asthma, Inhaled corticosteroids (ICS), Leukotriene modifier (LTA), Atopy.Abstract
BACKGROUND: Cytokines including Interleukin-5 play a key role in orchestrating the chronic inflammation of asthma. We aimed to determine the level of serum IL-5 in partly controlled atopic asthma in children and to assess the effect of different therapies on their levels.
METHODS: The study included 40 children aged 6-12 years with partly controlled asthma. Cases were randomly divided into two groups; group ‘A’ receiving Leukotriene modifiers and group ‘B’ receiving inhaled corticosteroids; each for two months. They were compared to 20 healthy non-asthmatic, matched controls. Serum IL-5 was measured for cases on the first visit and two months after therapy. Absolute eosinophilic count and serum Ig-E were determined. Pulmonary function testing was performed using spirometer at the beginning and two months after regular therapy.
RESULTS: Serum Interleukin-5 was significantly increased in asthmatic children during exacerbation and was significantly decreased after treatment. ROC curve analysis showed significant difference of IgE and PEFR after treatment with leukotriene modifier only.
CONCLUSION: Serum IL-5 seems to have a role in asthma pathogenesis. Efficiency of the two therapies (ICs & LTA) was similar in this group of patients. Both treatments led to significant decline in serum IL-5, IgE levels and eosinophilic count.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
American Lung Association: Asthma & Children Fact Sheet. Available at www.lungusa.org 1-800-LUNGUSA, Revised February 2010.
Zedan M, Settin A, Farag M, et al. Prevalence of bronchial asthma among egyption school children. Egyptian Journal of Bronchology. 2009; 3(2): 124-130.
Global Initiative for Asthma (GINA) Program: Pocket Guide for Asthma management and prevention. Available at www.ginasthma.org 2011. Pp8-11.
Asquith KL, Ramshaw HS, Hansbro PM, et al. The IL-3/IL-5/GM-CSF common b receptor plays a pivotal role in the regulation of Th2 immunity and allergic airway inflammation. J Immunol. 2008: 180(2):1199-1206. DOI: https://doi.org/10.4049/jimmunol.180.2.1199
Tomasiak-Åozowska MM, Bodzenta-Åukaszyk A, Tomasiak M, et al. The role of interleukin 13 and interleukin 5 in asthma. Postepy Hig Med Dosw. 2010; 64: 146-155.
Liu Andrew H, Joseph D, LeungDonald NM: Development and cross-sectional validation of the Childhood Asthma Control Test. J Allergy Clin Immunol. 2007; 119(4):817. DOI: https://doi.org/10.1016/j.jaci.2006.12.662
Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest. 2008;118: 3546–3556. DOI: https://doi.org/10.1172/JCI36130
Expert Panel Report 3. Guidelines for the Diagnosis and Management of Asthma: Section 2, Definition, Pathophysiology and Pathogenesis of Asthma, and Natural History of Asthma. Accessed August 28, 2007. aviable at http://www.nhlbi.nih.gov.
Kips JC. Cytokines in asthma. Eur Respir J. 2001; 18(Suppl. 34): 24s–33s. DOI: https://doi.org/10.1183/09031936.01.00229601
Jovanović S, ÄorÄ‘ević V and Ćosić V: Effects of inhaled glucocorticosteroids treatment on clinical and eosinophilic inflammstory parameters in patients with bronchial asthma. Acta Medica Medianae. 2010; 49(1):43-47.
Stelmach I, Bobrowska-Korzeniowska M, Majak P, et al. The effect of montelukast and different doses of budesonide on IgE serum levels and clinical parameters in children with newly diagnosed asthma. Pulmonary Pharmacology& Therapeutics. 2005; 18(5):374-380. DOI: https://doi.org/10.1016/j.pupt.2005.02.002
Yamakawa Y, Ohtsuka Y, Ohtani K, et al. Effects of Leukotriene Receptor Antagonists on Peripheral Eosinophil Counts and Serum IgE Levels in Children with Food Allergy. Drugs RD. 2010; 10 (3): 147-154. DOI: https://doi.org/10.2165/11586150-000000000-00000
Sandeep T, Roopakala MS, Silvia CRWD, et al. Evaluation of serum immunoglobulin E levels in bronchial asthma. Lung India. 2010; 27(3): 138–140. DOI: https://doi.org/10.4103/0970-2113.68312
Begum JA, Islam MI, Hoque SKA, et al. Relationship between IgE levels and lung function tests in children with asthma. J Dhaka Med Coll. 2010; 19(1): 3-6. DOI: https://doi.org/10.3329/jdmc.v19i1.6242
Barnes PJ. Corticosteroids, IgE, and atopy. J Clin Invest. 2001; 107(3):265–266. DOI: https://doi.org/10.1172/JCI12157
Sakuishi K, Oki S, Araki M, et al. Invariant NKT cells biased for IL-5 production act as crucial regulators of inflammation. J Immunol. 2007;179:3452. DOI: https://doi.org/10.4049/jimmunol.179.6.3452
Joseph J, Benedict S, Safa W, Joseph M: Serum interleukin-5 levels are elevated in mild and moderate persistent asthma irrespective of regular inhaled glucocorticoid therapy. BMC Pulm Med. 2004; 4:2. DOI: https://doi.org/10.1186/1471-2466-4-2
Huang CS, Chen SJ, Chung RL, Tang RB: Serum interleukin-5 measurements for monitoring acute asthma in children. J Asthma. 2005; 42(4):297-300. DOI: https://doi.org/10.1081/JAS-200057886
Kato M, Yamada Y, Maruyama K, Hayashi Y: Differential effects of corticosteroids on serum eosinophil cationic protein and cytokine production in rhinovirus- and respiratory syncytial virus-induced acute exacerbation of childhood asthma. Int Arch Allergy Immunol. 2011; 155(Suppl 1):77-84. DOI: https://doi.org/10.1159/000327434
Mahajan S and Mehta A: Role of Cytokines in Pathophysiology of Asthma. Iranian Journal of pharmacology and therapeutics. 2006; 5:1-14.
Pukelsheim K, Stoeger T, Kutschke D, et al. Cytokine Profiles in Asthma Families Depend on Age and Phenotype. PLoS One. 2010; 5(12):e14299. DOI: https://doi.org/10.1371/journal.pone.0014299
Xie Qing-ling, JIAO Wei, WEN Zhi-hong, et al. Effect of montelukast Na on serum and sputum eosinophil cationic protein and interleukin-5 in children with asthma. Clinical Focus J. 2005;08.
Riliang Z, Hongxi Z, Jinqin H: Effects of Formoterol,Montelukast and Zafirlukast on Secretory Activity of Peripheral Blood Mononuclear Cells in Patients with Asthma. Journal of Diagnostics. 2003; 1-16.
Hughes JM, Rimmer SJ, Salome CM, et al. Eosinophilia, interleukin-5 and tumour necrosis factor-alpha in asthmatic children. Allergy. 2001; 56 (5): 412-418. DOI: https://doi.org/10.1034/j.1398-9995.2001.056005412.x
Tang YJ, Xu YJ, Xiong SD, et al. The effect of inhaled glucocorticosteroid on protein kinase C alpha expression and interleukin-5 production in induced sputum inflammatory cells of asthma patients. Zhonghua Nei Ke Za Zhi. 2004; 43(11):849-52.
Karaman Ö, Sünneli L, Uzuner MN , et al. Evaluation of montelukast in 8 to 14 year old children with mild persistent asthma and compared with inhaled corticosteroids. Allergol et Immunopathol. 2004; 32(1):21-7. DOI: https://doi.org/10.1157/13057766
Olszowiec-Chlebna M, Majak P, Brzozowska A, et al. Effect of inhaled steroid and montelukast on clinical symptoms in children with newly diagnosed asthma: a pilot study. Pediatr Allergy and Immunology. 2010; 21:687–690. DOI: https://doi.org/10.1111/j.1399-3038.2009.00983.x
Garcia M. L, Wahn U, Gilles L, et al. Montelukast, Compared With Fluticasone, for Control of Asthma Among 6- to14-Year-Old Patients With Mild Asthma: The MOSAIC Study. Pediatrics. 2005; 116:360-369. DOI: https://doi.org/10.1542/peds.2004-1172
Meltzer E., Lockey R., Friedman B., et al. Fluticasone Propionate Clinical Research Study Group; Efficacy and Safety of Low-Dose Fluticasone Propionate Compared With Montelukast for Maintenance Treatment of Persistent Asthma. Mayo Clin Proc. 2002; 77: 437-445. DOI: https://doi.org/10.4065/77.5.437
Downloads
Published
How to Cite
Issue
Section
License
http://creativecommons.org/licenses/by-nc/4.0
